Sotorasib (Lumakras®) is a first-in-class oral medication FDA-approved for the treatment of adult patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. In order to be assessed for drug eligibility, a patient’s KRAS G12C positive status must first be determined by an FDA-approved companion diagnostics test including QIAGEN therascreen® KRAS RGQ PCR Kit or Guardant360® CDx prior to therapy initiation.1,2